AR112086A1 - Compuestos heteroaromáticos como inhibidores de vanina - Google Patents
Compuestos heteroaromáticos como inhibidores de vaninaInfo
- Publication number
- AR112086A1 AR112086A1 ARP180101573A ARP180101573A AR112086A1 AR 112086 A1 AR112086 A1 AR 112086A1 AR P180101573 A ARP180101573 A AR P180101573A AR P180101573 A ARP180101573 A AR P180101573A AR 112086 A1 AR112086 A1 AR 112086A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- compounds
- heteroaromatic compounds
- formulas
- Prior art date
Links
- 150000002390 heteroarenes Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Procesos para fabricar estos compuestos, las preparaciones farmacéuticas que contienen estos compuestos y sus métodos de uso. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), en donde A es un grupo de la fórmula (2) ó (3), en donde cada R¹, R², R³, R⁴, R⁵ y R⁶ se selecciona independientemente del grupo que consiste en H, C₁₋₄-alquilo, C₁₋₄-alquilo sustituido con un grupo hidroxilo o halógeno, fenilo y heteroarilo de 5 - 6 miembros, o R¹ y R², R³ y R⁴, o R⁵ y R⁶ juntos forman un carbociclo de 3 - 4 miembros, y en donde B se selecciona del grupo que consiste en las fórmulas (4), (5) y (6), en donde R⁷ es H, C₁₋₃-alquilo, halógeno, C₁₋₃-alcoxi, heteroarilo de 5 - 6 miembros, o R⁷ se selecciona del grupo que consiste en los compuestos de fórmulas (7), (8) y (9), en donde R⁸ se selecciona del grupo que consiste en C₁₋₆-alquilo, C₃₋₆-cicloalquilo y heterociclilo de 3 - 14 miembros, y X es CH₂ ó O; o una sal de aquel aceptable desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518106P | 2017-06-12 | 2017-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112086A1 true AR112086A1 (es) | 2019-09-18 |
Family
ID=62631060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101573A AR112086A1 (es) | 2017-06-12 | 2018-06-11 | Compuestos heteroaromáticos como inhibidores de vanina |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10364255B2 (es) |
| EP (1) | EP3638680B1 (es) |
| JP (1) | JP6880243B2 (es) |
| KR (1) | KR102607934B1 (es) |
| CN (1) | CN110770242B (es) |
| AR (1) | AR112086A1 (es) |
| AU (1) | AU2018285131B2 (es) |
| CA (1) | CA3066946A1 (es) |
| CL (1) | CL2019003515A1 (es) |
| CO (1) | CO2019013823A2 (es) |
| DK (1) | DK3638680T3 (es) |
| EA (1) | EA039223B1 (es) |
| ES (1) | ES2927021T3 (es) |
| HU (1) | HUE060597T2 (es) |
| IL (1) | IL271104B (es) |
| MA (1) | MA49374A (es) |
| MX (1) | MX394645B (es) |
| PE (1) | PE20200340A1 (es) |
| PH (1) | PH12019502693A1 (es) |
| PL (1) | PL3638680T3 (es) |
| TW (1) | TWI855993B (es) |
| WO (1) | WO2018228934A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3638680B1 (en) * | 2017-06-12 | 2022-08-10 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds as vanin inhibitors |
| RS65912B1 (sr) | 2018-08-13 | 2024-10-31 | Hoffmann La Roche | Nova heterociklična jedinjenja kao inhibitori monoacilglicerol lipaze |
| BR112021000650A2 (pt) * | 2018-08-28 | 2021-04-13 | Boehringer Ingelheim International Gmbh | Compostos heteroaromáticos como inibidores de vanina |
| US12240828B2 (en) | 2018-12-03 | 2025-03-04 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as vanin inhibitors |
| TWI838430B (zh) | 2018-12-03 | 2024-04-11 | 德商百靈佳殷格翰國際股份有限公司 | 作為vanin抑制劑之雜芳族化合物 |
| AU2019393953B2 (en) | 2018-12-03 | 2024-12-05 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
| JP7609854B2 (ja) | 2019-09-12 | 2025-01-07 | エフ． ホフマン－ラ ロシュ アーゲー | Ｍａｇｌ阻害剤としての４，４ａ，５，７，８，８ａ－ヘキサピリド［４，３－ｂ］［１，４］オキサジン－３－オン化合物 |
| US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| CN118892548A (zh) * | 2024-08-12 | 2024-11-05 | 中国人民解放军陆军特色医学中心 | Vanin-1抑制剂在制备治疗急性肾损伤继发急性肺损伤的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005035524A1 (en) * | 2003-10-09 | 2005-04-21 | Abbott Laboratories | Pyrrolidinyl urea derivatives as angiogensis inhibitors |
| WO2016193844A1 (en) * | 2015-05-29 | 2016-12-08 | Pfizer Inc. | Novel heterocyclic compounds as inhibitors of vanin-1 enzyme |
| CA3030381A1 (en) * | 2016-07-14 | 2018-01-18 | Pfizer Inc. | Pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
| EP3638680B1 (en) * | 2017-06-12 | 2022-08-10 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds as vanin inhibitors |
-
2018
- 2018-06-08 EP EP18731766.4A patent/EP3638680B1/en active Active
- 2018-06-08 MA MA049374A patent/MA49374A/fr unknown
- 2018-06-08 HU HUE18731766A patent/HUE060597T2/hu unknown
- 2018-06-08 DK DK18731766.4T patent/DK3638680T3/da active
- 2018-06-08 KR KR1020197038628A patent/KR102607934B1/ko active Active
- 2018-06-08 AU AU2018285131A patent/AU2018285131B2/en active Active
- 2018-06-08 PL PL18731766.4T patent/PL3638680T3/pl unknown
- 2018-06-08 JP JP2019566724A patent/JP6880243B2/ja active Active
- 2018-06-08 ES ES18731766T patent/ES2927021T3/es active Active
- 2018-06-08 EA EA202090014A patent/EA039223B1/ru unknown
- 2018-06-08 CN CN201880039562.3A patent/CN110770242B/zh active Active
- 2018-06-08 MX MX2019014876A patent/MX394645B/es unknown
- 2018-06-08 WO PCT/EP2018/065140 patent/WO2018228934A1/en not_active Ceased
- 2018-06-08 PE PE2019002531A patent/PE20200340A1/es unknown
- 2018-06-08 CA CA3066946A patent/CA3066946A1/en active Pending
- 2018-06-08 US US16/003,252 patent/US10364255B2/en active Active
- 2018-06-11 AR ARP180101573A patent/AR112086A1/es unknown
- 2018-06-11 TW TW107119946A patent/TWI855993B/zh active
-
2019
- 2019-05-13 US US16/410,037 patent/US20190263828A1/en not_active Abandoned
- 2019-11-28 PH PH12019502693A patent/PH12019502693A1/en unknown
- 2019-12-02 CL CL2019003515A patent/CL2019003515A1/es unknown
- 2019-12-02 IL IL271104A patent/IL271104B/en unknown
- 2019-12-09 CO CONC2019/0013823A patent/CO2019013823A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018228934A1 (en) | 2018-12-20 |
| JP6880243B2 (ja) | 2021-06-02 |
| ES2927021T3 (es) | 2022-11-02 |
| US10364255B2 (en) | 2019-07-30 |
| US20180354968A1 (en) | 2018-12-13 |
| EP3638680B1 (en) | 2022-08-10 |
| EP3638680A1 (en) | 2020-04-22 |
| DK3638680T3 (da) | 2022-09-05 |
| MX394645B (es) | 2025-03-21 |
| HUE060597T2 (hu) | 2023-04-28 |
| TW201920196A (zh) | 2019-06-01 |
| CL2019003515A1 (es) | 2020-06-19 |
| PE20200340A1 (es) | 2020-02-14 |
| CA3066946A1 (en) | 2018-12-20 |
| JP2020522517A (ja) | 2020-07-30 |
| CN110770242A (zh) | 2020-02-07 |
| EA039223B1 (ru) | 2021-12-20 |
| IL271104B (en) | 2022-03-01 |
| CN110770242B (zh) | 2022-08-19 |
| PH12019502693A1 (en) | 2020-07-13 |
| AU2018285131A1 (en) | 2019-10-31 |
| MX2019014876A (es) | 2020-02-13 |
| EA202090014A1 (ru) | 2020-05-12 |
| TWI855993B (zh) | 2024-09-21 |
| AU2018285131B2 (en) | 2021-11-11 |
| KR102607934B1 (ko) | 2023-12-01 |
| KR20200013718A (ko) | 2020-02-07 |
| IL271104A (en) | 2020-01-30 |
| US20190263828A1 (en) | 2019-08-29 |
| BR112019021703A2 (pt) | 2020-05-12 |
| CO2019013823A2 (es) | 2020-01-17 |
| PL3638680T3 (pl) | 2022-12-19 |
| MA49374A (fr) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112086A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR114164A1 (es) | Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| AR110405A1 (es) | Compuestos | |
| AR117229A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR112797A1 (es) | Inhibidores de kras g12c y métodos para utilizarlos | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| AR107488A1 (es) | Compuestos de benzopirazol y análogos de éstos | |
| AR103561A1 (es) | Fenilpiridinas herbicidas | |
| AR110088A1 (es) | Inhibidores de magl | |
| AR100702A1 (es) | Compuestos inhibidores de quinasa de unión tank | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
| AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
| AR101456A1 (es) | Inhibidores de cinasa c de proteína y métodos para usarse | |
| AR113929A1 (es) | Compuestos heterocíclicos | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR115906A1 (es) | Derivados de haloalilamina sulfona como inhibidores de lisil oxidasas | |
| AR114369A1 (es) | Dinucleótidos cíclicos como agentes antineoplásicos | |
| AR109706A1 (es) | INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |